Abstract
An immunohistochemical determination of the growth fraction (gf) with the ki-67 monoclonal antibody has been performed in a prospective series of 140 patients with primary operable breast carcinoma. Gf ranged from 0% to 43% ki-67 stained cells with a median value of 8%. High gf (> 8%) was significantly associated with axillary node involvement (p = 0.006), aneuploidy (p = 0.008), histologic grade (p = 0.03), and s-phase fraction > 5% determined by flow cytometry (p = 0.01). After a median follow-up of 6 years, the univariate analysis did not show significant correlation between high gf and worse relapse-free survival (p = 0.10) or shorter overall survival. However, a multivariate analysis on relapse-free survival, performed in 127 comparable patients, showed that gf was an independent predictive factor (p = 0.03) together with nodal status (p = 0.00001), age under 45 years (p = 0.0008), and chemotherapy (0.006). In node negative patients, gf was still an independent prognostic indicator (p = 0.002) together with age under 45 years (p = 0.0003). Tumor proliferative activity evaluated by the monoclonal antibody ki-67 appears to be an effective indicator of prognosis in breast cancer and could be of assistance in the decision making of adjuvant therapy in node negative patients.
Original language | English |
---|---|
Pages (from-to) | 57 |
Journal | Breast Cancer Research and Treatment |
Volume | 37 |
Issue number | S |
DOIs | |
Publication status | Published - 1 Jan 1996 |